Download
1 / 5
60 likes | 153 Vues
Dr. Michael Har-Noy plans to start a pivotal Phase II/III randomized study of AlloStimTM in the therapy of metastatic KRAS gene positive colon tumors. Dr. Michael Har-Noy notes there is no approved third line treatment for these patients. A favorable outcome of this study would likely lead to FDA marketing approval for AlloStimTM. Dr. Michael Har-Noy intends to start the study in the United States as well as two other international sites.
E N D
Dr. Michael Har-Noy’sAlloStimTM Is ScaleableWhile CAR-T Cells Are Not Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., biotech company in Israel, says that CAR-T therapy for a cancer patient must be produced using the patient’s own tumor cells and thus cannot be manufactured on a large scale.
Dr. Michael Har-Noy Notes That CAR-T Therapy Appears Less Effective In Solid Tumors Dr. Michael Har-Noy of Immunovative Therapies, Ltd. points out that early research indicates that CAR-T treatment has limited effectiveness in treating solid malignancies. Also, CAR-T therapy frequently causes serious toxic reactions. Dr. Michael Har-Noy notes that Immunovative Therapies, Ltd.’s AlloStimTM seems to have activity against most tested solid tumors. Dr. Michael Har-Noy says he will soon publish a Phase I/II study involving AlloStimTM treatment. Dr. Michael Har-Noy adds that unlike CAR-T therapy, AlloStimTM can be made in large amounts from any healthy donor’s blood. Therefore, AlloStimTM can be inexpensively produced in virtually unlimited quantities.
Dr. Michael Har-Noy Discusses AlloStimTM and Checkpoint Blockade Treatment Dr. Michael Har-Noy of Immunovative Therapies, Ltd. says that checkpoint blockade compounds interfere with molecules that malignant cells use to hide from a patient’s immune system. Yervoy and Opdivo are such checkpoint blockade drugs. Dr. Michael Har-Noy says, however, that checkpoint blockade agents work only if the patient has an intact immune response.
Dr. Michael Har-Noy Will Soon Start A Phase II/III Trial In Colorectal Tumors Dr. Michael Har-Noy plans to start a pivotal Phase II/III randomized study of AlloStimTM in the therapy of metastatic KRAS gene positive colon tumors. Dr. Michael Har-Noy notes there is no approved third line treatment for these patients. A favorable outcome of this study would likely lead to FDA marketing approval for AlloStimTM.
